News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Dhan Chand: BOT + BAL is redefining the treatment paradigm in colorectal cancer
Dhan Chand/LinkedIn
Jan 27, 2025, 07:20

Dhan Chand: BOT + BAL is redefining the treatment paradigm in colorectal cancer

Dhan Chand, Vice President of Research at Agenus, shared a post on LinkedIn:

“BOT + BAL is redefining the treatment paradigm in colorectal cancer, with unprecedented responses and no recurrences in the neoadjuvant setting.

 This approach is turning ‘cold’ tumors ‘hot’.

 For patients, this means a real chance at complete tumor clearance and new hope for a cancer-free future.”

Dhan Chand: BOT + BAL is redefining the treatment paradigm in colorectal cancer

Agenus cancer colorectal cancer Dhan Chand fight against cancer Global fight against cancer OncoDaily Oncology RadOnc
Special Coverage
Blog
Jun 3, 2025, 11:48
Aaron Mansfield Congratulates Frank Sinicrope and the Alliance team for impactful findings from the Atomic trial
Opinion
Jun 3, 2025, 11:46
Oyepeju Abioye-Akintola: It Was an Absolute Pleasure to Reconnect with Lynn Schuchter at ASCO 2025
Blog
Jun 3, 2025, 11:42
Pashtoon Kasi Shares Immunotherapy Insights for MSS Colorectal Cancer at ASCO 2025
Blog
Jun 3, 2025, 11:34
Armando Orlandi: Time to Challenge the Paradigm - CDK4/6 Inhibitors in Visceral Crisis 
Blog
Jun 3, 2025, 11:29
Bar Levy: ASCO 2025 - Latest Gynecologic Cancer Abstracts and Public Health and Patient Advocacy perspective
Blog
Jun 3, 2025, 11:20
Stephen V Liu: Randomized Phase 3 Trial of Time of Day of Immunotherapy Infusion
Insight
Jun 3, 2025, 11:15
Armando Orlandi: Day 4 at ASCO 2025 - Key Breast Cancer Clinical Advances 
Blog
Jun 3, 2025, 11:14
Jeff Ryckman Promoted to Associate Professor
Blog
Jun 3, 2025, 11:09
Rafeh Naqash: The Real Star Behind the Scenes who make ASCO a Success Every Year Every Time
Blog
Jun 3, 2025, 10:56
Giannis Mountzios: ASCO25 is About Science, Research, Care but Also Your Second Family - Colleagues and Friends
Blog
Jun 3, 2025, 10:50
Paolo Tarantino: We need Biomarkers to Tailor Treatment with T-DXd
Opinion
Jun 3, 2025, 10:41
TRIgnite-1 study at ASCO 2025 showed High Response Rates and Favorable Safety Profile for the Treatment of Relapsed/Refractory Multiple Myeloma with First-in-Class BCMA × CD38 × CD3 Trispecific Antibody